Parkinson's Disease
Updated: 06/16/2006

References

Abdel-Wahab MH. Potential neuroprotective effect of t-butylhydroquinone against neurotoxicity: induced by 1-methyl-4-(2’-methylphenyl)-1,2,3,6-tetrahydropyridine (2’-methyl-MPTP) in mice. J Biochem Mol Toxicol. 2005;19(1):32-41.

Abraham S, Soundararajan CC, et al. Erythrocyte antioxidant enzymes in Parkinson’s disease. Indian J Med Res. 2005 Feb;121(2):111-5.

Adams CR, Ziegler DK, et al. Mercury intoxication simulating amyotrophic lateral sclerosis. JAMA. 1983 Aug 5;250(5):642-3.

Akbar M, Calderon F, et al. Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):10858-63.

American Parkinson Disease Association Inc. Available at: www.apdaparkinson.org. Accessed March 14, 2006.

Antolin I, Mayo JC, et al. Protective effect of melatonin in a chronic experimental model of Parkinson’s disease. Brain Res. 2002 Jul 12;943(2):163-73.

Atasoy HT, Nuyan O, et al. T2-weighted MRI in Parkinson’s disease: substantia nigra pars compacta hypointensity correlates with the clinical scores. Neurol India. 2004 Sep;52(3):332-7.

Azuma T, Nagai Y, et al. The effect of dehydroepiandrosterone sulfate administration on patients with multi-infarct dementia. J Neurol Sci. 1999 Jan 1;162(1):69-73.

Bardin JA, Eisen EE, et al. Case-control studies of liver, gallbladder and pancreatic cancer and metalworking fluid exposure in the automobile industry. Paper presented at: 128th Annual Meeting of the American Public Health Association; November 14, 2000; Washington, DC.

Beal MF. Bioenergetic approaches for neuroprotection in Parkinson’s disease. Ann Neurol. 2003;53(suppl 3):S39-S47; discussion S47-S8.

Bender DA, Earl CJ, et al. Niacin depletion in Parkinsonian patients treated with L-dopa, benserazide and carbidopa. Clin Sci (Lond). 1979 Jan;56(1):89-93.

Benedetti MD, Bower JH, et al. Smoking, alcohol, and coffee consumption preceding Parkinson’s disease: a case-control study. Neurology. 2000 Nov 14;55(9):1350-8.

Brown DJ. Characterizing Risk at Metal Finishing Facilities:1998. Washington DC: Environmental Protection Agency; 1998. May Report EPA/600/R-97/111.

Castorina M, Ferraris L. Acetyl-L-carnitine affects aged brain receptorial system in rodents. Life Sci. 1994;54(17):1205-14.

Chacon JR, Duran E, et al. Usefulness of olanzapine in the levodopa-induced psychosis in patients with Parkinson’s disease [in Spanish]. Neurologia. 2002 Jan;17(1):7-11.

Checkoway H, Powers K, et al. Parkinson’s disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol. 2002 Apr 15;155(8):732-8.

Chen ST, Chuang JI, et al. Melatonin attenuates MPP+-induced neurodegeneration and glutathione impairment in the nigrostriatal dopaminergic pathway. J Pineal Res. 2002 May;32(4):262-9.

Chong ZZ, Kang JQ, et al. Essential cellular regulatory elements of oxidative stress in early and late phases of apoptosis in the central nervous system. Antioxid Redox Signal. 2004 Apr;6(2):277-87.

Clayman CB, ed. The American Medical Association Encyclopedia of Medicine. New York, NY: Random House; 1989.

Coimbra CG, Junqueira VB. High doses of riboflavin and the elimination of dietary red meat promote the recovery of some motor functions in Parkinson’s disease patients. Braz J Med Biol Res. 2003 Oct;36(10):1409-17.

Cyr M, Calon F, et al. Drugs with estrogen-like potency and brain activity: potential therapeutic application for the CNS. Curr Pharm Des. 2000 Aug;6(12):1287-312.

Deleu D. Smoking, alcohol, and coffee consumption preceding Parkinson’s disease. Neurology. 2001 Apr 10;56(7):984-5.

De Simone R, Ramacci MT, et al. Effect of acetyl-L-carnitine on forebrain cholinergic neurons of developing rats. Int J Dev Neurosci. 1991;9(1):39-46.

Duan W, Ladenheim B, et al. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson’s disease. J Neurochem. 2002 Jan;80(1):101-10.

Fahn S. An open trial of high-dosage antioxidants in early Parkinson’s disease. Am J Clin Nutr. 1991 Jan;53(suppl 1):S380-S382.

Fahn S. A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson’s disease. Ann Neurol. 1992;32(suppl):S128-S132.

Fariss MW, Zhang JG. Vitamin E therapy in Parkinson’s disease. Toxicology. 2003 Jul 15;189(1-2):129-46.

Fishman PS, Oyler GA. Significance of the parkin gene and protein in understanding Parkinson’s disease. Curr Neurol Neurosci Rep. 2002 Jul;2(4):296-302.

Foreman PJ, Perez-Polo JR, et al. Effects of acetyl-L-carnitine treatment and stress exposure on the nerve growth factor receptor (p75NGFR) mRNA level in the central nervous system of aged rats. Prog Neuropsycholpharmacol Biol Psychiatry. 1995 Jan;19(1):117-33.

Garcia-Escrig M, Bermejo Pareja F, et al. Levodopa-induced psychosis in patients with idiopathic Parkinson disease [in Spanish]. Med Clin (Barc). 1999 Feb 27;112(7):245-50.

Gehlen WMJ. Treatment of levodopa psychosis with L-tryptophan. Dtsch Med Wochenschr. 1974;99(10):457-63.

Genedani S, Rasio G, et al. Studies on homocysteine and dehydroepiandrosterone sulphate plasma levels in Alzheimer’s disease patients and in Parkinson’s disease patients. Neurotox Res. 2004;6(4):327-32.

Gentry LO. Bacterial resistance. Orthop Clin North Am. 1991 Jul;22(3):379-88.

Golbe LI, Farrell TM, et al. Case-control study of early life dietary factors in Parkinson’s disease. Arch Neurol. 1988 Dec;45(12):1350-3.

Goncharova ND, Oganyan TE, et al. Functions of the hypothalamo-hypophyseal-adrenal system in aging female monkeys. Neurosci Behav Physiol. 2000 Nov;30(6):717-21.

Gotz ME, Gerstner A, et al. Altered redox state of platelet coenzyme Q10 in Parkinson’s disease. J Neural Transm. 2000;107(1):41-8.

Goyer RA. Toxic and essential metal interactions. Annu Rev Nutr. 1997;17:37-50.

Growdon JH, Melamed E, et al. Effects of oral L-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson’s disease. Life Sci. 1982 Mar 8;30(10):827-32.

Heller A, Won L, et al. Long-chain fatty acids increase cellular dopamine in an immortalized cell line (MN9D) derived from mouse mesencephalon. Neurosci Lett. 2005 Mar 7;376(1):35-9.

Hirsch MA, Toole T, et al. The effects of balance training and high-intensity resistance training on persons with idiopathic Parkinson's disease. Arch Phys Med Rehabil. 2003 Aug;84(8):1109-17.

Hsu M, Srinivas B, et al. Glutathione depletion resulting in selective mitochondrial complex I inhibition in dopaminergic cells is via an NO-mediated pathway not involving peroxynitrite: implications for Parkinson’s disease. J Neurochem. 2005 Mar;92(5):1091-103.

Jimenez-Jimenez FJ, Molina JA, et al. Serum levels of coenzyme Q10 in patients with Parkinson’s disease. J Neural Transm. 2000;107(2):177-81.

Kasper DL, Braunwald E, et al, eds. Harrison’s Principles of Internal Medicine. 16th ed. New York, NY: McGraw-Hill; 2004.

Khaldy H, Escames G, et al. Synergistic effects of melatonin and deprenyl against MPTP-induced mitochondrial damage and DA depletion. Neurobiol Aging. 2003;24:491-500.

Kidd PM. Neurodegeneration from mitochondrial insufficiency: nutrients, stem cells, growth factors, and prospects for brain rebuilding using integrative management. Altern Med Rev. 2005 Dec;10(4):268-93.

Koller WC, Cersosimo MG. Neuroprotection in Parkinson’s disease: an elusive goal. Curr Neurol Neurosci Rep. 2004 Jul;4(4):277-83.

Kurth MC, Tetrud JW, et al. Oral levodopa/carbidopa solution versus tablets in Parkinson’s patients with severe fluctuations: a pilot study. Neurology. 1993 May;43(5):1036-9.

Linert W, Jameson GN. Redox reactions of neurotransmitters possibly involved in the progression of Parkinson’s disease. J Inorg Biochem. 2000 Apr;79(1-4):319-26.

Logroscino G, Marder K, et al. Dietary lipids and antioxidants in Parkinson’s disease: a population-based, case-control study. Ann Neurol. 1996 Jan;39(1):89-94.

Lyons KE, Pahwa R. Long-term benefits in quality of life provided by bilateral subthalamic stimulation in patients with Parkinson’s disease. J Neurosurg. 2005;103:252-5.

Mally J, Stone TW. The effect of theophylline on parkinsonian symptoms. J Pharm Pharmacol. 1994 Jun;46(6):515-7.

Mazzio E, Huber J, et al. Effect of antioxidants on L-glutamate and N-methyl-4-phenylpyridinium ion induced-neurotoxicity in PC12 cells. Neurotoxicology. 2001 Apr;22(2):283-8.

McFadden SA. Phenotypic variation in xenobiotic metabolism and adverse environmental response: focus on sulfur-dependent detoxification pathways. Toxicology. 1996 Jul 17;111(1-3):43-65.

Mizuta E, Kuno S. Rotations induced by L-dopa in parkinsonian rats are reduced by an ingestion of amino acids. J Neural Transm Park Dis Dement Sect. 1993;6(3):211-4.

Muller T, Buttner T, et al. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson’s disease. Neurosci Lett. 2003 May 8;341(3):201-4.

Mytilineou C, Han SK, et al. Toxic and protective effects of L-dopa on mesencephalic cell cultures. J Neurochem. 1993 Oct;61(4):1470-8.

Nadlinger K, Birkmayer J, et al. Influence of reduced nicotinamide adenine dinucleotide on the production of interleukin-6 by peripheral human blood leukocytes. Neuroimmunomodulation. 2001;9(4):203-8.

Pardo B, Mena MA, et al. Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants. Brain Res. 1995 Jun 5;682(1-2):133-43.

PDR. The PDR Pocket Guide to Prescription Drugs. 5th ed. New York, NY: Pocket Books/Simon & Schuster; 2002.

Petroni ML, Albani G, et al. Body composition in advanced-stage Parkinson’s disease. Acta Diabetol. 2003 Oct;40(suppl 1):S187-S190.

Pettegrew JW, Levine J, et al. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer’s disease and geriatric depression. Mol Psychiatry. 2000 Nov;5(6):616-32.

Philpott DJ, Girardin SE, et al. Innate immune responses of epithelial cells following infection with bacterial pathogens. Curr Opin Immunol. 2001 Aug;13(4):410-6.

Powers KM, Smith-Weller T, et al. Parkinson’s disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology. 2003 Jun 10;60(11):1761-6.

Purves D, Augustine GJ, et al, eds. Neuroscience. 2nd ed. Sunderland, Mass: Sinauer Associates, Inc; 2001.

Rabey JM, Vardi J, et al. L-tryptophan administration in L-dopa-induced hallucinations in elderly Parkinsonian patients. Gerontology. 1977;23(6):438-44.

Rascol O, Brooks DJ, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa: 056 Study Group. N Engl J Med. 2000 May 18;342(20):1484-91.

Riederer P. L-dopa competes with tyrosine and tryptophan for human brain uptake. Nutr Metab. 1980;24(6):417-23.

Roghani M, Behzadi G. Neuroprotective effect of vitamin E on the early model of Parkinson’s disease in rat: behavioral and histochemical evidence. Brain Res. 2001 Feb 16;892(1):211-7.

Ross GW, Petrovitch H, et al. Parkinsonian signs and substantia nigra neuron density in decendents elders without PD. Ann Neurol. 2004 Oct;56(4):532-9.

Sakagami H, Satoh K, et al. Interaction between sodium ascorbate and dopamine. Free Radic Biol Med. 1998 Dec;25(9):1013-20.

Sandyk R. L-tryptophan in neuropsychiatric disorders: a review. Int J Neurosci. 1992 Nov;67(1-4):127-44.

Sandyk R, Pardeshi R. Pyridoxine improves drug-induced parkinsonism and psychosis in a schizophrenic patient. Int J Neurosci. 1990 Jun;52(3-4):225-32.

Schulz JB, Henshaw DR, et al. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Exp Neurol. 1995 Apr;132(2):279-83.

Seitz G, Gebhardt S, et al. Ascorbic acid stimulates DOPA synthesis and tyrosine hydroxylase gene expression in the human neuroblastoma cell line SK-N-SH. Neurosci Lett. 1998 Mar 6;244(1):33-6.

Shults CW, Flint Beal M, et al. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson’s disease. Exp Neurol. 2004 Aug;188(2):491-4.

Shults CW, Haas RH, et al. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol. 1997 Aug;42(2):261-4.

Shults CW, Oakes D, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002 Oct;59(10):1541-50.

Silverman, HM Ed. The Pill Book. 9th ed. New York, New York: Bantam Books: CMD Publishing; 2000.

Smargiassi A, Mutti A, et al. A case-control study of occupational and environmental risk factors for Parkinson’s disease in the Emilia-Romagna region of Italy. Neurotoxicology. 1998 Aug;19(4-5):709-12.

Soto-Otero R, Mendez-Alvarez E, et al. Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson’s disease. J Neurochem. 2000 Apr;74(4):1605-12.

Steele PE, Tang PH, et al. Clinical laboratory monitoring of coenzyme Q10 use in neurologic and muscular diseases. Am J Clin Pathol. 2004 Jun;121(suppl):S113-S120.

Sullivan A, Edlund C, et al. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis. 2001 Sep;1(2):101-14.

Sutoo D, Akiyama K. Regulation of brain function by exercise. Neurobiol Dis. 2003 Jun;13(1):1-14. Review.

Taglialatela G, Navarra D, et al. Acetyl-L-carnitine treatment increases nerve growth factor levels and choline acetyltransferase activity in the central nervous system of aged rats. Exp Gerontol. 1994 Jan-Feb;29(1):55-66.

Tancrede C. Role of human microflora in health and disease. Eur J Clin Microbiol Infect Dis. 1992 Nov;11(11):1012-5.

Van Vaerenbergh J, Vranken R, et al. The influence of rotational exercises on freezing in Parkinson's disease. Funct Neurol. 2003 Jan-Mar;18(1):11-6.

Weinreb O, Mandel S, et al. Neurological mechanisms of green tea polyphenols in Alzheimer’s and Parkinson’s diseases. J Nutr Biochem. 2004 Sep;15(9):506-16.

Yapa SC. Detection of subclinical ascorbate deficiency in early Parkinson’s disease. Public Health. 1992 Sep;106(5):393-5.

Young G, Conquer J. Omega-3 fatty acids and neuropsychiatric disorders. Reprod Nutr Dev. 2005 Jan;45(1):1-28.

Zecca L, Youdim MB, et al. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci. 2004 Nov;5(11):863-73.

Zisapel N. Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting. Cell Mol Neurobiol. 2001 Dec;21(6):605-16.

Zuber M, Alperovitch A. Parkinson’s disease and environmental factors [in French]. Rev Epidemiol Sante Publique. 1991;39(4):373-87.